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ющие дезинтоксивационные препараты (реосорбилакт) 400 
мл, парацетамол 500 мг внутривенно. Следует подчеркнуть, 
что применеие инфузионной терапии не снижало терапевти-
ческого эффекта парентерального интерферона.
Отсутствие побочных реакций отмечено у 17 (32,6%) па-
циенток, и, следует отметить, что чаще отсутствие реакции 
отмечалось у женщин с высокими титрами вирусной инфек-
ции (герпес, папилломавирус), что, возможно, является по-
казателем иммуносупрессивного состояния либо снижения 
собственной продукции эндогенного интерферона у этих 
пациенток. Данное предположение может послужить осно-
ванием для дальнейших исследований.
Таким образом, проведенное клиническое исследование 
показало высокую эффективность применения ɑ-интерфе-
рона-2b в комплексе терапии хламидиоза, мико- и уреаплаз-
менной инфекции. В большинстве случаев, с применеием 
интерферонотерапии, мы наблюдали элиминацию папил-
ломавируса, вируса простого герпеса и цитомегаловируса, 
значительное снижения бактериальной контаминации.
Выводы
1. Интерферонотерапию следует включать в комплекс 
терапии микст-инфекций гениталий, применение ɑ-интер-
ферона-2b при лечении хронических инфекций является эф-
фективным и патогенетически обоснованным.
2. Курс терапии бактериальной инфекции включает 
применение ɑ-интерферона-2b не менее 1млн в сутки 10 
дней, хламидиоза 1млн.в сутки 10-20 дней, герпетической 
инфекции 1-2млн. в сутки 10-20 дней, папилломавирусной 
инфекции 3 млн в сутки 10 дней, при повторном положи-
тельном результате проводится курс в объеме 30 млн (3 млн 
в сутки 10 дней). После терапии интерфероном курс лече-
ния может быть продолжен индукторами интерферона.
3. Лечение внутриклеточных форм инфекции, виру-
сов и вирусных ассоциаций требует назначения интерферо-
нотерапии в качестве «заместительной» терапии недостатка 
естественных факторов иммунитета, способствующих эли-
минации данных возбудителей.
4. Назначение ɑ-интерферона-2b (альфарекина) по-
зволяет достичь полной ликвидации хламидийной инфек-
ции, элиминации вируса папилломы человека.
5. В последующем, в периоде реабилитации рекомен-
дуется проведение курсов иммуномодуляторов, вакцинации 
специфическими противовирусными вакцинами.
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ABSTRACT
It is analyzed the factors of progression of metabolic disorders in the liver and the changes in intracardiac hemodynamics in pa-
tients with nonalcoholic fatty liver disease in combination with hypertension. The predictors of progression of metabolic disorders 
in the liver in case of NAFLD associated with AH are the following: ALT activity; the level of total cholesterol; VLDL; HOMA-IR 
index; BMI and the presence of diastolic dysfunction due to disorders of diastolic relaxation; left ventricular systolic dysfunction 
with a decrease of contractile ability; left ventricular remodeling that contributes to the development and progression of liver fibrosis 
and increases the risk of cardiovascular complications.
Keywords: arterial hypertension, nonalcoholic fatty liver disease, metabolic disorders, the structural and functional changes in 
the myocardium.
The topicality of the problem of nonalcoholic fatty liver 
disease (NAFLD) and arterial hypertension (AH) comorbidity is 
caused by the high rates of their prevalence and progression of 
complications [1]. At present time, NAFLD is the most common 
liver disease and one of the leading factors in the development 
of chronic diseases. According to modern concepts, NAFLD is 
positioned as an independent risk factor for the development and 
progression of cardiovascular (CV) disease (CVD) and CVD, 
in turn, is one of the most important causes of morbidity and 
mortality in patients with NAFLD [7].
The fact that CV risk factors are more common in patients with 
NAFLD is not accidental, as «fatty liver» is responsible for the 
implementation of the metabolic components of cardiovascular 
risk, such as very low density lipoproteins (VLDL), C-reactive 
protein (CP) and the components of blood clotting. On the other 
hand, association of CVD with obesity indirectly affects the 
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progression of metabolic disorders in the liver by the secretory 
activity of adipose tissue [7]. 
The combination of NAFLD with hypertension, of course, 
has a mutually potentiating effect on the course of both diseases: 
NAFLD increases the rate of development of fibrotic changes in 
the liver parenchyma and the formation of portal hypertension, 
and at the same time an organ damage and the development of 
structural and functional disorders of the myocardium associated 
with the progression of hypertension are going on [3].
The joint pathogenetic mechanisms of AH and NAFLD include 
insulin resistance (IR) and compensatory hyperinsulinemia, 
which in turn stimulates the production of growth factors (platelet 
factor, insulin-like factor, fibroblast growth factor), which leads 
to proliferation of smooth muscle cells and fibroblasts, and in the 
end causes vasoconstriction, increases blood pressure (BP) and 
induces fibrosis [2,10].
The presence of AH in patients with NAFLD is an additional 
risk factor for the progression of dyslipidemia (DL), IR, 
deterioration of carbohydrate metabolism and liver function that 
are associated with excess body weight, which also worsens 
the course of the disease and contributes to the development of 
complications [5].
It was found that hypertension is an independent predictor 
of formation of portal fibrosis in patients with NAFLD, where 
the leading role belongs to angiotensin II and activation of 
transforming growth factor generation (TGF- β1) [8].
In recent years, certain data were obtained about the high risk 
of development of cardiometabolic disorders in the myocardium 
of patients with NAFLD and hypertension. The presence of 
pro-inflammatory status and atherogenic DL in these patients 
suggests a possible joint pathogenetic link between hepatic 
steatosis, DL and atherosclerosis. [6]
Therefore, a great scientific and practical interest is riveted to 
the study of structural and functional changes of the myocardium 
in patients with combined course of NAFLD and AH [4].
Currently, studies are being conducted that will allow to 
find out whether the accumulation of fat in the liver causes IR 
of myocardium, or maybe it causes myocardial steatosis and 
metabolic disorders of the heart with the assistance of humoral 
mechanisms which closely correlate with fat content in the liver.
Thus, fatty liver is closely related to IR, atherosclerosis and 
metabolic disorders. And hepatic steatosis is a predictor of CV 
events [3].
These mechanisms provide more evidence about the 
relationship between NAFLD and IR syndrome. IR provides 
the network, in which the clinical significance of progression 
of atherosclerotic vascular lesions is implemented. However, 
it is still not fully understood what metabolic events exactly 
contribute to the emergence of CV events against the background 
of NAFLD [4].
Despite considerable interest in this issue, the publications 
devoted to the study of factors affecting the progression of 
NAFLD in patients with AH, are contradictory. The uncertainty 
of the prognosis of NAFLD combined with AH regarding the 
impact of various metabolic disorders on the development and 
progression of hepatic steatosis and cardiac hemodynamics 
disorders dictates the need to find early markers and predictors, 
that are responsible for the initiation of an inflammatory process 
in the liver, as well as for the development of structural and 
functional changes in the myocardium.
The purpose of the research was to study the causative factors 
for progression of metabolic disorders in the liver and changes of 
intracardiac hemodynamics in patients with NAFLD combined 
with AH.
Materials and methods. The study involved 65 patients with 
NAFLD (37 men and 28 women). The mean age of patients 
was 56,4 ± 4,6 years. Depending on the nosology, patients were 
divided into 2 groups, representative by gender and age. The first 
group included patients with isolated NAFLD (n = 31), second (n 
= 34) - with combined course of NAFLD and AH of 2nd degree.
The patients were examined by a single program, which 
consisted of evaluating of physical findings (analysis of 
complaints, history taking, examination and evaluation of 
anthropometric indices, the calculation of body mass index 
(BMI) according to Quetelet formula). Laboratory studies 
included the study of the functional state of the liver (the activity 
of alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), γ-glutamyl-transpeptidase (GGT) in the blood serum 
by conventional means); assessment of lipid spectrum of blood 
serum.
Serum insulin level was determined by immune-enzyme 
assay ELISA (DRG kits, USA). Assessment of IR level was 
performed using HOMA (homeostasis model assesment) with 
the calculation of IR index (HOMA-IR) using the formula: 
HOMA-IR = insulin, mcU / mL * glucose, mmol / L / 22.5.
The contents of total cholesterol (TC), triglycerides (TG), 
high density lipoproteins (HDL) in the blood serum were 
determined by enzymatic colorimetric method using «Human» 
kits (Germany); very low density lipoproteins (VLDL), low 
density lipoproteins (LDL) and atherogenic index (AI) were 
determined according to the conventional calculation method.
The concentration of fasting plasma glucose (FPG) was 
determined by glucose-oxidase method. The concentration of 
CRP in the blood serum was determined by enzyme immunoassay 
with the «DRG» set of reagents (USA).
Transthoracic echocardiography was performed by using the 
diagnostic system «Phillips IU» (USA) according to standard 
procedures in the M and B modes, using the recommendations 
of the American Society of Echocardiography to estimate the 
main indicators: end-systolic volume (ESV) of the left ventricle 
(LV), end-diastolic volume (EDV) of the LV, left ventricular 
end-systolic dimension (ESD), left ventricular end-diastolic 
dimension (EDD), left ventricular stroke volume (SV), ejection 
fraction (EF). LV diastolic function was assessed at the time of 
registration of transmitral diastolic flow in pulsed wave Doppler 
regimen.
The data of 20 healthy individuals (control group), 
comparable in age and gender with the examined patients, 
were used to evaluate the obtained results. Statistical analysis 
was performed by MS Excel v 7.0 using the Student’s t test, 
with the minimum accepted level of significance p <0.05. A 
correlation analysis with the calculation of Pearson’s correlation 
coefficient and Spearman’s rank correlation coefficient was used 
to determine the relationships between variables.
Results and discussion. The indexes of systolic (SBP) and 
diastolic (DBP) pressure in patients of groups 1 and 2 were the 
following, respectively: SBP, mm Hg – 126.9 ± 3.4 and 158.6 ± 
4.8 (control group 118.4 ± 2.6 (p <0.05); DBP, mm Hg – 80.2 ± 
4.3 and 94.2 ± 3.4 (control group 73.4 ± 2.2 (p <0.05).
The analysis of anthropometric parameters found a significant 
increase of BMI (in groups 1 and 2: 32.4 ± 1.8 kg / m² and 36.2 
± 4.8 kg / m², respectively; control group 22.3 ± 1.8 kg / m² 
(p <0.05)). At the same time, BMI of patients of group 2 with 
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combined course of NAFLD and hypertension was significantly 
higher (p <0,05) than the one in patients with isolated NAFLD. 
The analysis of the functional state of liver in patients of 
groups 1 and 2 was characterized by intensification of cytolytic 
processes in the liver, which were most expressed in patients 
with a combination of NAFLD and AH, that testified to the 
mutual aggravating character of metabolic disorders and high 
risk of formation of fibrotic changes in the liver (Table 1). 
Table 1.
The peculiarities of blood serum biochemical indexes of examined patients (M± m)
Index, units of measurement Control group (n=20) NAFDL (n=31) NAFDL+AH (n=34)
AST,  mmol/L 0.36±0.05 0.47±0.06 0.64±0.7*/# 
ALT, mmol/L 0.48±0.07 0.56±0.07 0.78±0.5*/# 
GGTP, МU/L 43.7±12.7 57.1±15.2* 61.8±18.6*/# 
НОМА-IR 1.6±1.3 3.6±1.8* 5.1±2.6*/# 
TG, mmol/L 1.2±0.4 3.1±0.2* 4.3±0.6*/# 
TC, mmol/L 4.2±0.8 6.2±0.4* 7.1±0.6*/# 
HDL, mmol/L 1.3±0.06 1.1±0.05 0.72±0.03*/ #
LDL, mmol/L 3.0±0.21 3.36±0.3 4.1±0.4*/#
Thrombocytes, 109/L 226.0±23 220.0±24 200.0±44*/# 
Fibronectin, mcg/mL 337.2±7.8 395.0±8.2* 484.0±9.8*/# 
СRP, mg/L 2.85±0.21 6.45±0.28* 8.44±0.34*/#
Notes:
* - P <0.05 - significant differences in comparison with the control group;
# - P <0.05 - significant differences in comparison with patients with NAFLD
The level of CRP in blood serum exceeded the reference 
values in both groups of examined patients. The greatest 
increase was observed in patients with combined course of AH 
and NAFLD. A correlation of CRP with the following indexes 
was established: BMI (r = 0.47; p <0.001), the level of the FPG 
(r = 0.44; p <0.001), ALT (r = 0.49; p <0.001), TG (r = 0.37; 
p <0.04), HOMA-IR index (r = 0.41; p <0.001). The level of 
CRP should be considered as an additional prognostic criterion 
for increased risk of cardiovascular events in case of combined 
course of NAFLD and hypertension against the background of 
obesity.
The changes of hepatic transaminases also depended on BMI 
and were more pronounced in patients with combined course of 
NAFLD and hypertension.
A decrease of insulin sensitivity according to the HOMA-
IR criterion was found in both groups of patients. Maximum 
values were observed in group 2 (p <0.05) and they positively 
correlated with BMI (r = 0.44; p <0.001), and the level of TG (r 
= 0.39; p <0.001).
The disorders, identified in our research, confirm the data 
that the pathological processes that occur in the liver in case of 
NAFLD lead to disruption of apoptosis and contribute to the 
development of systemic metabolic changes [9]. 
Changes of lipid metabolism were significantly more frequent 
in patients of group 2 with the combined course of NAFLD and 
AH, in comparison with patients of group 1 (82.3% and 46.20%, 
respectively; p <0.05). The level of total cholesterol in patients 
of group 2 was significantly higher than the one in comparison 
group and the control group as well (p <0.05) (Table 1).
An increase of concentration of total cholesterol and 
triglycerides in the group 1 directly depended on BMI (r = 0.61, 
p <0.05; r = 0.64, p <0.05, respectively), which is associated 
with the progression of metabolic disorders in the liver, in 
particular, with an excess intake of fats and carbohydrates in the 
liver, which are transformed into fatty acids that are substrates 
for the synthesis of TG. This confirms the theory regarding the 
influence of DL on the progression of NAFLD [10].
It was found that the decline of HDL in patients with NAFLD 
and hypertension was observed significantly more frequently 
and was more pronounced than in group 1 (groups 1 and 2: 
20.0% and 54.2%; p <0.05, respectively). 
Significant disorders of coagulation hemostasis were found 
in examined patients. Thus, patients with combined course of 
NAFLD and AH had 1.4-fold elevated serum levels of fibronectin 
compared with the control group (p <0.05).
Since fibronectin is a protein of extracellular matrix and a 
marker of severity of mesenchymal inflammation [5], these 
changes indicate the presence of the hypercoagulable syndrome 
in patients with NAFDL, and in combination with hypertension 
it contributes to further progression of apoptosis of the liver cells, 
strengthening of IR, development and deepening of hypoxia of 
cardiomyocytes, activation of free radical lipid oxidization [3]. 
There was a significant (p <0.05) reduction of platelets in the 
blood serum of patients with combined course of  hypertension 
and NAFLD in comparison with the control group, which may 
indirectly indicate a high risk of fibrosis formation in these 
patients.
Thus, overweight, DL, IR, systemic inflammation and the 
presence of hypertension are the main predictors of progression 
of metabolic disorders in the liver and the deterioration of its 
functional state. 
The analysis of echocardiographic parameters of patients of 
both groups showed the presence of structural, functional and 
hemodynamic disturbances, the severity of which was greater in 
patients with a combination of NAFLD and hypertension (Table 
2).
A decrease of early (E) and late (A) diastolic filling velocities 
was going on in both groups of patients: (E, groups 1 and 2: 
0.96 m / c and 0.74 m / c, respectively; control group 1.21 m 
/ c (p <0.05)); (A, groups 1 and 2: 0.91 m / c and 0.78 m / c, 
respectively; control group 1.10 m / c (p <0.05)), which was 
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more pronounced in patients with a combination of NAFLD and 
hypertension.
Тable 2
Hemodynamic indexes of patients with NAFDL and combination of NAFDL and AH (M±m)
Indexes Control group, (n=20) NAFDL (n=31) NAFDL+AH (n=34)
EDV, cm3 118.1±5.4 131.2±4.7* 162.4±5.6*#
ESV, сm3 47.4±2.3 58.3±5.2* 76.4±0.8*#
LV EDD, сm 4.32±0.03 4.89±0.06* 5.38±0.05*#
LV ESD, сm 3.26 ±0.02 3.92 ±0.02* 4.29±0.04*#
Stroke volume (SV), сm3 75.4 ±1.36 78.9±1.38 96.6±0.76*#
Ejection fraction (EF),% 65.2±1.41 61.3±2.16 56.9±1.48*#
* – p<0.05  – significance of differences compared with the control group;  
# – p<0.05  – significance of differences in comparison with NAFDL patients
The state of cardiohemodynamics in both groups of patients 
with NAFLD was significantly worse than the one of the control 
group and had certain differences between the patients with 
isolated NAFLD and the ones with combination of NAFLD 
and hypertension. The LV ESD index progressively increased 
in patients of groups 1 and 2 compared with the control group, 
and the difference between groups was significant (p <0.05). The 
increase of EDV occurred in both groups and was maximal in 
patients with NAFLD and hypertension, significantly exceeding 
the indexes of group 1 as well as the ones of the control group. 
Diastolic function was worse in patients with a combination 
of NAFLD and hypertension than in patients of group 1. Also, 
patients with a combination of NAFLD and hypertension had 
significantly higher indexes of ESV and EDV.
When evaluating the velocity and timing parameters of the 
systole and diastole we noted a decrease of  transmitral flow 
maximum velocity during atrial systole phase: 1.2-fold  in 
patients of group 1 and 1.3-fold in patients of group 2. Also, a 
1.4-fold increase of the left atrium systole phase duration was 
detected in both groups of patients. Along with these, patients of 
group 2 had 1.2-fold shortening of mechanical diastole.
Confirmed LV dysfunction in patients with isolated NAFDL 
and combined course of NAFLD and hypertension was 
unidirectional and corresponded to diastolic dysfunction of type 
I.
Thus, the combination of NAFLD and hypertension causes 
structural, functional and hemodynamic changes, which are 
characterized by diastolic dysfunction due to the disorders 
of diastolic myocardial relaxation, as well as compensatory 
preclinical systolic dysfunction of LV with decreased contractile 
ability and increased end-diastolic left ventricular compliance.
Comparison of laboratory data, the parameters of intracardiac 
hemodynamics,  structural and functional characteristics of the 
myocardium in patients with isolated course of NAFLD and 
NAFLD comorbid with hypertension demonstrates the highest 
activity of the inflammatory process in the liver in patients 
with combined course of NAFLD and hypertension, which is 
associated with the risk of development and progression of liver 
fibrosis. This effect is intensified under the influence of lipid and 
carbohydrate metabolism disorders, IR, hypercoagulation and 
systemic inflammation.
Conclusion.
1. The course of NAFLD associated with AH is accompanied 
by the atherogenic DL, IR, systemic inflammation, impaired 
carbohydrate metabolism that are connected with disorders of 
intracardiac hemodynamics, structural and functional changes in 
the myocardium.
2. The predictors of progression of metabolic disorders in the 
liver in case of NAFLD associated with AH are the following: ALT 
activity; the level of total cholesterol; VLDL; HOMA-IR index; 
BMI and the presence of diastolic dysfunction due to disorders 
of diastolic relaxation; left ventricular systolic dysfunction with 
a decrease of contractile ability; left ventricular remodeling that 
contributes to the development and progression of liver fibrosis 
and increases the risk of cardiovascular complications.
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ABSTRACT
The selenium concentration and free radical status in blood serum were studied in patients with acute-on-chronic liver failure of
alcoholic etiology. This patient group had decreased selenium in blood serum (the average value 75,0±20,1 mcg/l). With the increase
of staging of the pathological process, the depth of selenium deficiency in patients increases. Plasma concentration of selenium re-
mained unchanged after the treatment. Decrease of selenium is characterized by activation of free radical processes in blood serum
of these patients. 
Keywords: acute-on-chronic liver failure, alcoholic liver disease, selenium, free radical oxidation
Acute-on-chronic liver failure (ACLF) is a kind of pathology
that combines acute hepatitis on a background of alcoholic
cirrhosis [1]. According to a prospective multi-center study, the
active alcohol intake in the last 3 months prior to the aggravation
is the most common reason that leads to an exacerbation of
chronic liver failure (42,9%). In addition, alcoholic cirrhosis
(58,4%) observed in these patients more often than cirrhosis of
viral etiology (14,8%) and mixed (9,3%) [5]. 
In the pathogenesis of the acute is the basic process of
free-radical oxidation, in contrast to which there antioxidant
antiradical system, the main elements of which are selenium-
containing enzymes [8, 9]. 
Prolonged duration of alcoholic liver disease and a high
probability of death determine this pathology as a socially
significant disease [6]. Investigation of the mechanisms of
change of free radical and selenium status would make it
possible to introduce additional diagnostic criteria of the disease
and ways of their medical correction [7]. 
The aim of the study is to evaluate the selenium and free
radical statuses of blood serum of patients with acute-on-chronic
liver failure of alcoholic etiology for the optimization of the
diagnostic of this nosology.  
Materials and methods
We examined 60 patients aged 23 to 74 years (mean age
48,8±11,2 years) with acute-on-chronic liver failure of alcoholic
etiology 1-3rd stages, exhibited according to the criteria of the
American Association for the Study of Liver Diseases (AASLD).
After clinical and laboratory examination, all patients received
standard basic therapy. Re-examination of patients was carried
out after 15 days. Exclusion criteria were patients with chronic
viral hepatitis and decompensated chronic diseases of other
etiologies.
Comparison group consisted of 21 men (mean age - 47,6±12,5
years) without clinical signs of pathology of the hepatobiliary
system, living together with patients and the same feed with
them, to eliminate differences in exogenous selenium admission.
We used the CAGE questionnaire and Alcohol Use Disorders
Identification Test for detecting chronic alcohol intoxication. 
The selenium content in the blood serum was adjusted
by fluorimetric method on N.A. Golubkina (1995) [3].
Chemiluminescence (CML) method was used for integral
assessment of free radical oxidation of blood serum. We
studied the spontaneous and induced Fe CML, identifying [2]:
lightsum for 1 minute spontaneous CML (Ssp); lightsum (Sind-
1) for 2 minutes after the «fast» flash; a maximum of «fast»
flashes (h) induced by CML. We analyzed the kinetics of CML,
initiated H202 in the presence of luminol [2], by the following
parameters: lightsum for 2 minutes CML (Sind-2). the maximum
of luminescence (H). The intensity of the CML was measured
in relative units. Registration CML was performed on the
fluorescent spectrometer LS 50B («Perkin Elmer»).
The data were processed by Microsoft Office Excel 2010
software, Statistica 6.03. Calculate: mean (M), standard
deviation (SD), confidence limits (CL). Statistical significance
of differences between mean values was estimated by Mann-
Whitney test. Determining the link between non-parametric
values was assessed by Spearman correlation analysis. The
critical level of significance in hypothesis was p<0,05.
Results and discussion. Average serum selenium level
in patients with acute-on-chronic liver failure of alcoholic
etiology was 75,5±20,1 mcg/l and was lowered as compared
with the comparison group 105,8±13,6 mcg/l (p<0,00001). The
distribution of provision of selenium in the examined patients is
displayed in Figure 1. 
 
